Literature DB >> 33452453

Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells.

Shouheng Lin1,2,3, Xuchao Zhang4, Guohua Huang5, Lin Cheng2,3, Jiang Lv2, Diwei Zheng2, Simiao Lin2, Suna Wang2, Qiting Wu2, Youguo Long2, Baiheng Li6, Wei Wei7, Pentao Liu8, Duanqing Pei2,3, Yangqiu Li9, Zhesheng Wen10, Shuzhong Cui11, Peng Li2,3, Xiaofang Sun12,13, Yilong Wu14, Yao Yao15.   

Abstract

Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune activities and facilitate cancer progression. Although the concept of immunosuppressive MDSCs is well established, the mechanism that MDSCs regulate non-small cell lung cancer (NSCLC) progression through the paracrine signals is still lacking. Here, we reported that the infiltration of MDSCs within NSCLC tissues was associated with the progression of cancer status, and was positively correlated with the Patient-derived xenograft model establishment, and poor patient prognosis. Intratumoral MDSCs directly promoted NSCLC metastasis and highly expressed chemokines that promote NSCLC cells invasion, including CCL11. CCL11 was capable of activating the AKT and ERK signaling pathways to promote NSCLC metastasis through the epithelial-mesenchymal transition (EMT) process. Moreover, high expression of CCL11 was associated with a poor prognosis in lung cancer as well as other types of cancer. Our findings underscore that MDSCs produce CCL11 to promote NSCLC metastasis via activation of ERK and AKT signaling and induction of EMT, suggesting that the MDSCs-CCL11-ERK/AKT-EMT axis contains potential targets for NSCLC metastasis treatment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33452453     DOI: 10.1038/s41388-020-01605-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Myeloid-derived suppressor cell heterogeneity and subset definition.

Authors:  Elisa Peranzoni; Serena Zilio; Ilaria Marigo; Luigi Dolcetti; Paola Zanovello; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

2.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.

Authors:  Christiane Meyer; Laurène Cagnon; Carla M Costa-Nunes; Petra Baumgaertner; Nicole Montandon; Loredana Leyvraz; Olivier Michielin; Emanuela Romano; Daniel E Speiser
Journal:  Cancer Immunol Immunother       Date:  2013-12-20       Impact factor: 6.968

3.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

4.  A novel subset of B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC.

Authors:  Guangbo Zhang; Haitao Huang; Yibei Zhu; Gehua Yu; Xin Gao; Yunyun Xu; Cuiping Liu; Jianquan Hou; Xueguang Zhang
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

5.  Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.

Authors:  Hong-Li Sun; Xin Zhou; Yi-Feng Xue; Ke Wang; Yun-Feng Shen; Jing-Jue Mao; Hong-Feng Guo; Zong-Ning Miao
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

Review 6.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Authors:  Douglas Marvel; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

Review 7.  Emerging Biological Principles of Metastasis.

Authors:  Arthur W Lambert; Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.

Authors:  Ang Huang; Bo Zhang; Bo Wang; Fan Zhang; Ke-Xing Fan; Ya-Jun Guo
Journal:  Cancer Immunol Immunother       Date:  2013-06-13       Impact factor: 6.968

Review 10.  Myeloid-derived suppressor cells-new and exciting players in lung cancer.

Authors:  Zhenzhen Yang; Jiacheng Guo; Lanling Weng; Wenxue Tang; Shuiling Jin; Wang Ma
Journal:  J Hematol Oncol       Date:  2020-01-31       Impact factor: 17.388

View more
  9 in total

1.  Prognostic Value of Dual-Time-Point [18F]FDG PET/CT for Predicting Distant Metastasis after Treatment in Patients with Non-Small Cell Lung Cancer.

Authors:  Sang Mi Lee; Jeong Won Lee; Ji-Hyun Lee; In Young Jo; Su Jin Jang
Journal:  J Pers Med       Date:  2022-04-07

2.  Intranasal Delivery of Recombinant S100A8 Protein Delays Lung Cancer Growth by Remodeling the Lung Immune Microenvironment.

Authors:  Sze Wing Wong; Joshua McCarroll; Kenneth Hsu; Carolyn L Geczy; Nicodemus Tedla
Journal:  Front Immunol       Date:  2022-05-17       Impact factor: 8.786

3.  Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies.

Authors:  Shouheng Lin; Lin Cheng; Wei Ye; Shanglin Li; Diwei Zheng; Le Qin; Qiting Wu; Youguo Long; Simiao Lin; Suna Wang; Guohua Huang; Peng Li; Yao Yao; Xiaofang Sun
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

4.  Cancer-Associated Fibroblasts Promote Tumor Aggressiveness in Head and Neck Cancer through Chemokine Ligand 11 and C-C Motif Chemokine Receptor 3 Signaling Circuit.

Authors:  Wen-Yen Huang; Yaoh-Shiang Lin; Yu-Chun Lin; Shin Nieh; Yi-Ming Chang; Tsai-Yu Lee; Su-Feng Chen; Kuender D Yang
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

Review 5.  Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.

Authors:  Daniel L Pouliquen; Alice Boissard; Cécile Henry; Olivier Coqueret; Catherine Guette
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

6.  The road of NSCLC stem cells toward bone metastases.

Authors:  Giulia Bertolini; Ilaria Roato
Journal:  Bone Rep       Date:  2022-09-05

Review 7.  Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.

Authors:  Carlo Genova; Chiara Dellepiane; Paolo Carrega; Sara Sommariva; Guido Ferlazzo; Paolo Pronzato; Rosaria Gangemi; Gilberto Filaci; Simona Coco; Michela Croce
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

Review 8.  Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.

Authors:  Sagun Parakh; Matthias Ernst; Ashleigh R Poh
Journal:  Cancers (Basel)       Date:  2021-12-11       Impact factor: 6.639

9.  An Integrative Pan-Cancer Analysis of Kinesin Family Member C1 (KIFC1) in Human Tumors.

Authors:  Hao Wu; Yingjuan Duan; Siming Gong; Qiang Zhu; Xuanyou Liu; Zhenguo Liu
Journal:  Biomedicines       Date:  2022-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.